The Simplici-T1 trial (NCT03335371), designed to explore the safety and efficacy of TTP399 as an oral adjunctive therapy for T1DM, showed that addition of TTP399 to an optimized insulin regimen produced a statistically significant improvement in HbA1c (-0.32%, p<0.01) and Daytime Time In Range (8%, p<0.05) relative to placebo. The treat-to-target (FPG: ~80-130mg/dL; post meal glucose: <180-200 mg/dL) design of the study allowed changes in insulin dose after the insulin-optimization period. To evaluate the effect that these changes could have on A1c, several pre-planned analyses were performed. A positive correlation was observed between reduction in A1c and both reduction in total insulin (p=0.008) (Figure 1) and bolus insulin dose (p=0.004) in the TTP399-treated group but not in the PBO group. A subgroup analysis, matching on changes in insulin use reveals that, relative to PBO, those treated with TTP399 who maintained the optimized insulin regimen improved A1c by -0.35%, p=0.04 (41%TTP399; 36% PBO). The group that reduced their total insulin dose by more than 0.06U/Kg (i.e.,>10% reduction in total and >20% reduction in bolus insulin dose; 47% TTP399; 33% PBO) improved A1c by -0.41%, p=0.013. These improvements occurred without increasing ketones in plasma or hypoglycemic events. During the 12-week treatment period, 12% of the TTP399 group and 31%of the PBO increased their insulin dose.


C. Valcarce: Employee; Self; vTv Therapeutics. J.L. Freeman: Employee; Self; vTv Therapeutics. Stock/Shareholder; Self; vTv Therapeutics. Stock/Shareholder; Spouse/Partner; vTv Therapeutics. I. Dunn: None. K. Klein: None. J.B. Buse: Consultant; Self; Cirius Therapeutics, CSL Behring, Neurimmune. Research Support; Self; American Diabetes Association, National Institutes of Health, Novo Nordisk A/S, Patient-Centered Outcomes Research Institute, Sanofi, Tolerion, Inc., vTv Therapeutics. Stock/Shareholder; Self; Mellitus Health, Pendulum Therapeutics, PhaseBio Pharmaceuticals, Inc., Stability Health. Other Relationship; Self; ADOCIA, AstraZeneca, Dance Biopharm Holdings, Inc., Eli Lilly and Company, MannKind Corporation, NovaTarg Therapeutics, Novo Nordisk A/S, Senseonics, Inc, vTv Therapeutics, Zafgen, Inc.


JDRF; vTv Therapeutics; National Institutes of Health (UL1TR002489)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at